[{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of California, Irvine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Irvine \/ Merck & Co"},{"orgOrder":0,"company":"Virtua Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Virtua Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtua Health \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Virtua Health \/ Merck & Co"},{"orgOrder":0,"company":"Stony Brook University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Stony Brook University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stony Brook University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Stony Brook University \/ Merck & Co"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Neostigmine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of California, Irvine

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          University of California, Irvine

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Intestinal Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 01, 2023

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Virtua Health

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Virtua Health

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Nausea and Vomiting.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 08, 2017

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuromuscular Blockade.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 30, 2017

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          University of Melbourne

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          University of Melbourne

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase IV

                          Sponsor : Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2017

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Melbourne Health | Peter MacCallum Cancer Centre | Royal Hospital For Women | Northpark Private Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Stony Brook University

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Stony Brook University

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuromuscular Blockade.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 21, 2016

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Endeavor Health

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Endeavor Health

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 05, 2015

                          Lead Product(s) : Neostigmine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank